A detailed history of Los Angeles Capital Management LLC transactions in Alector, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 56,286 shares of ALEC stock, worth $276,364. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,286
Previous 63,186 10.92%
Holding current value
$276,364
Previous $286,000 8.39%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$4.34 - $6.58 $29,946 - $45,402
-6,900 Reduced 10.92%
56,286 $262,000
Q2 2024

Aug 05, 2024

BUY
$4.19 - $6.23 $18,561 - $27,598
4,430 Added 7.54%
63,186 $286,000
Q4 2023

Feb 06, 2024

SELL
$3.77 - $8.39 $420,136 - $934,998
-111,442 Reduced 65.48%
58,756 $468,000
Q3 2023

Nov 06, 2023

BUY
$5.2 - $8.77 $885,029 - $1.49 Million
170,198 New
170,198 $1.1 Million
Q1 2023

May 04, 2023

SELL
$5.85 - $9.84 $273,686 - $460,354
-46,784 Reduced 18.8%
202,110 $1.25 Million
Q4 2022

Feb 06, 2023

SELL
$6.88 - $9.55 $49,536 - $68,760
-7,200 Reduced 2.81%
248,894 $2.3 Million
Q3 2022

Nov 02, 2022

BUY
$8.19 - $13.2 $1.88 Million - $3.04 Million
229,951 Added 879.59%
256,094 $2.42 Million
Q2 2022

Aug 05, 2022

SELL
$7.65 - $14.24 $25,099 - $46,721
-3,281 Reduced 11.15%
26,143 $266,000
Q1 2022

May 06, 2022

BUY
$13.02 - $20.78 $383,100 - $611,430
29,424 New
29,424 $419,000
Q3 2020

Nov 02, 2020

SELL
$10.54 - $24.96 $95,492 - $226,137
-9,060 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$21.87 - $33.11 $6,779 - $10,264
310 Added 3.54%
9,060 $221,000
Q1 2020

May 04, 2020

BUY
$16.25 - $35.28 $142,187 - $308,700
8,750 New
8,750 $211,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $405M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.